Precursors  ||| S:0 E:11 ||| NNP
of  ||| S:11 E:14 ||| IN
breast  ||| S:14 E:21 ||| JJ
cancer  ||| S:21 E:28 ||| NN
It  ||| S:28 E:31 ||| PRP
has  ||| S:31 E:35 ||| VBZ
become  ||| S:35 E:42 ||| VBN
apparent  ||| S:42 E:51 ||| JJ
that  ||| S:51 E:56 ||| IN
estrogen  ||| S:56 E:65 ||| JJ
receptor  ||| S:65 E:74 ||| NN
( ||| S:74 E:75 ||| -LRB-
ER ||| S:75 E:77 ||| NNP
)  ||| S:77 E:79 ||| -RRB-
-  ||| S:79 E:81 ||| CD
positive  ||| S:81 E:90 ||| JJ
and  ||| S:90 E:94 ||| CC
-  ||| S:94 E:96 ||| CD
negative  ||| S:96 E:105 ||| JJ
breast  ||| S:105 E:112 ||| NN
lesions  ||| S:112 E:120 ||| NNS
are  ||| S:120 E:124 ||| VBP
completely  ||| S:124 E:135 ||| RB
distinct  ||| S:135 E:144 ||| JJ
diseases ||| S:144 E:152 ||| NNS
.  ||| S:152 E:154 ||| .
Precursors  ||| S:154 E:165 ||| NNP
of  ||| S:165 E:168 ||| IN
low-grade  ||| S:168 E:178 ||| JJ
breast  ||| S:178 E:185 ||| NN
cancer  ||| S:185 E:192 ||| NN
are  ||| S:192 E:196 ||| VBP
low-grade  ||| S:196 E:206 ||| JJ
premalignant  ||| S:206 E:219 ||| JJ
lesions ||| S:219 E:226 ||| NNS
,  ||| S:226 E:228 ||| ,
usually  ||| S:228 E:236 ||| RB
ER  ||| S:236 E:239 ||| NNP
and  ||| S:239 E:243 ||| CC
progesterone  ||| S:243 E:256 ||| JJ
receptor  ||| S:256 E:265 ||| NN
( ||| S:265 E:266 ||| -LRB-
PR ||| S:266 E:268 ||| NNP
)  ||| S:268 E:270 ||| -RRB-
positive  ||| S:270 E:279 ||| JJ
and  ||| S:279 E:283 ||| CC
HER2  ||| S:283 E:288 ||| CD
negative ||| S:288 E:296 ||| JJ
.  ||| S:296 E:298 ||| .
On  ||| S:298 E:301 ||| IN
the  ||| S:301 E:305 ||| DT
other  ||| S:305 E:311 ||| JJ
hand ||| S:311 E:315 ||| NN
,  ||| S:315 E:317 ||| ,
precursors  ||| S:317 E:328 ||| VBG
of  ||| S:328 E:331 ||| IN
high-grade  ||| S:331 E:342 ||| JJ
breast  ||| S:342 E:349 ||| NN
cancer  ||| S:349 E:356 ||| NN
are  ||| S:356 E:360 ||| VBP
high-grade  ||| S:360 E:371 ||| JJ
premalignant  ||| S:371 E:384 ||| JJ
lesions ||| S:384 E:391 ||| NNS
,  ||| S:391 E:393 ||| ,
usually  ||| S:393 E:401 ||| RB
ER  ||| S:401 E:404 ||| NNP
and  ||| S:404 E:408 ||| CC
PR  ||| S:408 E:411 ||| NNP
negative  ||| S:411 E:420 ||| JJ
and  ||| S:420 E:424 ||| CC
HER2  ||| S:424 E:429 ||| CD
positive ||| S:429 E:437 ||| JJ
.  ||| S:437 E:439 ||| .
Lobular  ||| S:439 E:447 ||| JJ
neoplasia  ||| S:447 E:457 ||| NNS
( ||| S:457 E:458 ||| -LRB-
LN ||| S:458 E:460 ||| NNP
)  ||| S:460 E:462 ||| -RRB-
and  ||| S:462 E:466 ||| CC
ductal  ||| S:466 E:473 ||| JJ
carcinoma  ||| S:473 E:483 ||| NN
in  ||| S:483 E:486 ||| IN
situ  ||| S:486 E:491 ||| NNS
( ||| S:491 E:492 ||| -LRB-
DCIS ||| S:492 E:496 ||| NNP
)  ||| S:496 E:498 ||| -RRB-
are  ||| S:498 E:502 ||| VBP
important  ||| S:502 E:512 ||| JJ
from  ||| S:512 E:517 ||| IN
the  ||| S:517 E:521 ||| DT
clinical  ||| S:521 E:530 ||| JJ
point  ||| S:530 E:536 ||| NN
of  ||| S:536 E:539 ||| IN
view ||| S:539 E:543 ||| NN
.  ||| S:543 E:545 ||| .
LN  ||| S:545 E:548 ||| NNP
increases  ||| S:548 E:558 ||| VBZ
the  ||| S:558 E:562 ||| DT
risk  ||| S:562 E:567 ||| NN
of  ||| S:567 E:570 ||| IN
bilateral  ||| S:570 E:580 ||| JJ
breast  ||| S:580 E:587 ||| NN
cancer ||| S:587 E:593 ||| NN
.  ||| S:593 E:595 ||| .
This  ||| S:595 E:600 ||| DT
is  ||| S:600 E:603 ||| VBZ
why  ||| S:603 E:607 ||| WRB
the  ||| S:607 E:611 ||| DT
recommendation  ||| S:611 E:626 ||| NN
for  ||| S:626 E:630 ||| IN
the  ||| S:630 E:634 ||| DT
treatment  ||| S:634 E:644 ||| NN
of  ||| S:644 E:647 ||| IN
LN  ||| S:647 E:650 ||| NNP
is  ||| S:650 E:653 ||| VBZ
very  ||| S:653 E:658 ||| RB
different  ||| S:658 E:668 ||| JJ
-   ||| S:668 E:671 ||| NN
from  ||| S:671 E:676 ||| IN
just  ||| S:676 E:681 ||| RB
following  ||| S:681 E:691 ||| RB
up  ||| S:691 E:694 ||| RB
up  ||| S:694 E:697 ||| RB
to  ||| S:697 E:700 ||| TO
bilateral  ||| S:700 E:710 ||| JJ
mastectomy ||| S:710 E:720 ||| NN
.  ||| S:720 E:722 ||| .
The  ||| S:722 E:726 ||| DT
complete  ||| S:726 E:735 ||| JJ
surgical  ||| S:735 E:744 ||| JJ
excision  ||| S:744 E:753 ||| NN
of  ||| S:753 E:756 ||| IN
the  ||| S:756 E:760 ||| DT
lesion  ||| S:760 E:767 ||| NN
with  ||| S:767 E:772 ||| IN
negative  ||| S:772 E:781 ||| JJ
margins  ||| S:781 E:789 ||| NNS
is  ||| S:789 E:792 ||| VBZ
the  ||| S:792 E:796 ||| DT
usual  ||| S:796 E:802 ||| JJ
treatment  ||| S:802 E:812 ||| NN
of  ||| S:812 E:815 ||| IN
DCIS ||| S:815 E:819 ||| NNP
.  ||| S:819 E:821 ||| .
Several  ||| S:821 E:829 ||| JJ
big  ||| S:829 E:833 ||| JJ
randomized  ||| S:833 E:844 ||| JJ
clinical  ||| S:844 E:853 ||| JJ
trials  ||| S:853 E:860 ||| NNS
showed  ||| S:860 E:867 ||| VBD
the  ||| S:867 E:871 ||| DT
benefit  ||| S:871 E:879 ||| NN
of  ||| S:879 E:882 ||| IN
adjuvant  ||| S:882 E:891 ||| JJ
radiotherapy  ||| S:891 E:904 ||| NNS
( ||| S:904 E:905 ||| -LRB-
RT ||| S:905 E:907 ||| NNP
) ||| S:907 E:908 ||| -RRB-
.  ||| S:908 E:910 ||| .
Some  ||| S:910 E:915 ||| DT
of  ||| S:915 E:918 ||| IN
them  ||| S:918 E:923 ||| PRP
suppose  ||| S:923 E:931 ||| VBP
that  ||| S:931 E:936 ||| IN
there  ||| S:936 E:942 ||| EX
is  ||| S:942 E:945 ||| VBZ
a  ||| S:945 E:947 ||| DT
group  ||| S:947 E:953 ||| NN
of  ||| S:953 E:956 ||| IN
patients  ||| S:956 E:965 ||| NNS
who  ||| S:965 E:969 ||| WP
do  ||| S:969 E:972 ||| VBP
not  ||| S:972 E:976 ||| RB
need  ||| S:976 E:981 ||| VB
adjuvant  ||| S:981 E:990 ||| JJ
treatment ||| S:990 E:999 ||| NN
.  ||| S:999 E:1001 ||| .
The  ||| S:1001 E:1005 ||| DT
benefit  ||| S:1005 E:1013 ||| NN
of  ||| S:1013 E:1016 ||| IN
adjuvant  ||| S:1016 E:1025 ||| JJ
tamoxifen  ||| S:1025 E:1035 ||| NN
is  ||| S:1035 E:1038 ||| VBZ
clear  ||| S:1038 E:1044 ||| RB
only  ||| S:1044 E:1049 ||| RB
for  ||| S:1049 E:1053 ||| IN
patients  ||| S:1053 E:1062 ||| NNS
with  ||| S:1062 E:1067 ||| IN
ER  ||| S:1067 E:1070 ||| NNP
positive  ||| S:1070 E:1079 ||| JJ
disease ||| S:1079 E:1086 ||| NN
.  ||| S:1086 E:1088 ||| .
The  ||| S:1088 E:1092 ||| DT
UK ||| S:1092 E:1094 ||| NNP
/  ||| S:1094 E:1096 ||| NNP
ANZ  ||| S:1096 E:1100 ||| NNP
study  ||| S:1100 E:1106 ||| NN
showed  ||| S:1106 E:1113 ||| VBD
the  ||| S:1113 E:1117 ||| DT
benefit  ||| S:1117 E:1125 ||| NN
of  ||| S:1125 E:1128 ||| IN
tamoxifen  ||| S:1128 E:1138 ||| VBG
only  ||| S:1138 E:1143 ||| RB
in  ||| S:1143 E:1146 ||| IN
patients  ||| S:1146 E:1155 ||| NNS
without  ||| S:1155 E:1163 ||| IN
RT ||| S:1163 E:1165 ||| NNP
.  ||| S:1165 E:1167 ||| .
